-
Eur Radiol: How to use radiomics to improve the prediction of survival of patients with glioblastoma?
Time of Update: 2021-03-19
1007/s00330-020-07335-1 Yangsean Choi,Yoonho Nam, Jang Jinhee, et Al Radiomics on May Increase Survival the prognostic value for patients in glioblastoma When Combined with Conventional Clinical and prognostic Genetic Models the DOI:.
-
Nat Commun: RNF167 targets the degradation of CASTOR1 and activates mTORC1 to promote tumor development
Time of Update: 2021-03-19
RNF167-mediated ubiquitination and AKT1-mediated phosphorylation promote the occurrence and development of breast cancerBreast cancerFurther studies have shown that several cell types with higher CASTOR1 expression are not sensitive to the regulation of arginine.
-
Nature BME: Long-term activation of innate immune pathways by multivalent STING agonists
Time of Update: 2021-03-19
In summary, this study emphasizes the use of synthetic polymers to induce STING condensation to activate natural immune pathways to exert anti-tumor effects .
The use of synthetic polymers to induce STING condensation to activate the innate immune pathway to exert anti-tumor effects.
-
The first case in China!
Time of Update: 2021-03-19
Recently, the first domestic “Magnetic Resonance-guided Laser Ablation of Brain Metastases (LITT)” (hereinafter referred to as “laser ablation”) was successfully implemented by the team of Professor Jia Wang from the Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University.
-
Eur Radiol: How to use clinical and CT findings to predict the prognosis of patients with periampullary carcinoma?
Time of Update: 2021-03-19
1007/s00330-020-07316-4">Yoen ,Jung Hoon Kim,Bo Hur yun, et Al Prediction of Survival of tumor Recurrence and Poor Clinical ampullary adenocarcinomas and the using the preoperative CT findings.
-
Inovio announces the first phase III clinical success of innovative DNA immunotherapy treatment for cervical cancer
Time of Update: 2021-03-19
Inovio announced the positive results of the first phase III clinical trial of VGX-3100 for cervical precancerous lesions.
INOVIO announced in early January this year: For the precancerous lesions of the vulva caused by HPV infection, the Phase II clinical trial showed good clinical effectiveness, safety and tolerability.
-
Nature Communications: The success of the prostate cancer treatment predictive model paves the way for individualized medicine
Time of Update: 2021-03-19
They first created a new xenograft derived from an early patient, and then tested 74 different drugs on the organoids of this graft and other experimental tumor models-a total of 13 were identified to reduce prostate cancer Cell viability compounds.
-
J Clin Oncol: A new model for local, regional and distant recurrence prediction in patients with thin (T1) melanoma
Time of Update: 2021-03-19
02446">Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas .
02446">Development and Validation of Nomograms to Predict Local , Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas in this message
-
JAHA: Childhood cancer promotes arteriosclerosis and its characteristics in survivors
Time of Update: 2021-03-19
The data of this study indicate that the vascular compliance of childhood cancer survivors may be different from the known concept of arteriosclerosis in the population, and tumor growth and anti-tumor treatment may be determinants of their pathobiological characteristics .
-
Lancet oncol: Is the secondary cytoreductive surgery beneficial to platinum-sensitive recurrent ovarian cancer?
Time of Update: 2021-03-19
For patients with platinum-sensitive recurrent ovarian cancer, compared with chemotherapy alone, secondary cytoreductive surgery followed by chemotherapy can significantly prolong the progression-free survival of patients.
For patients with platinum-sensitive recurrent ovarian cancer, compared with chemotherapy alone, secondary cytoreductive surgery followed by chemotherapy can significantly prolong the progression-free survival of patients.
-
Eur Radiol: What is the difference between the prognosis of patients with dilated and non-dilated cholangiopathies with PTBD?
Time of Update: 2021-03-19
The technical success rate, technical data (lateral position, fluoroscopy time, radiation dose, amount of contrast medium, use of disposable equipment), surgery-related complications, and perioperative mortality were compared between patients with dilated bile ducts and those with non-dilated bile ducts.
-
Takeda will acquire Maverick Therapeutics to promote T-cell conjugation therapy for solid tumors and expand its new immuno-oncology product portfolio
Time of Update: 2021-03-19
com/ct/CT?id=smartlink&url=https%3A%2F%2F">TSE:4502/NYSE:TAK ) ("Takeda") today announced the exercise of its option to acquire a privately-owned biopharmaceutical company pioneering conditional active bispecific T cell targeted immunotherapy Maverick Therapeutics, Inc.
-
Lancet oncol: Comparison of two first-line chemotherapy regimens for patients with recurrent/metastatic head and neck squamous cell carcinoma!
Time of Update: 2021-03-19
A phase 2 trial of the TPEx chemotherapy regimen (Docetaxel-platinum-cetuximab) showed that patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) have a median overall survival of up to 14 months.
-
Nat Commun: Study on the risk of breast cancer in BRCA1/BRCA2 mutation carriers
Time of Update: 2021-03-19
1038/s41467-020-20496-3">A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers .
1038/s41467-020-20496-3">A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers Leave a message here
-
The anti-PD-1 monoclonal antibody drug "Paampril" showed excellent results in the mid-term clinical trial of phase III
Time of Update: 2021-03-19
combined with chemotherapy for the first-line treatment of patients with squamous non-small cell lung cancer III The interim analysis of the phase clinical trial showed excellent results, reaching the expected objective remission rate main research endpoint.
-
Neuro Oncol: Hormone therapy will worsen the overall survival and progression-free survival of patients with brain metastases!
Time of Update: 2021-03-19
This study aims to conduct a systematic literature review and meta-analysis of the relationship between steroid therapy and overall survival (OS) in BM patients treated with ICI.
-
Ten months after the introduction of anti-tumor products was approved for marketing, the cooperation was terminated for US$20 million
Time of Update: 2021-03-19
Previous public reports showed that as early as August 2018, Beihai Kangcheng signed an exclusive license agreement with Puma Bio for the development and commercialization of neratinib in mainland China, Taiwan, Hong Kong and Macau.
-
NEJM: In 70 years of ups and downs, the status of albumin infusion in the treatment of liver cirrhosis will be rewritten!
Time of Update: 2021-03-19
For patients hospitalized with decompensated liver cirrhosis, infusion of albumin to increase the albumin level to the goal of ≥30g/L is not more beneficial than the current standard care.
-
Eur Radiol: What is the novelty of cone beam breast CT in evaluating breast cancer?
Time of Update: 2021-03-18
The molecular subtypes of breast cancer and the number of focal lesions, lesion type, tumor size, lesion density, internal enhancement mode, lesion enhancement degree ( ΔHU), tumor shape, edge burrs, calcification, calcification distribution, and increase in peripheral blood vessels are significant Correlation (all p<0.
-
Nat Commun: The response of transplanted tumors and organoid models from prostate cancer patients to treatment
Time of Update: 2021-03-18
Establishment of transplanted tumor modelIn this study, the researchers constructed an in situ treated soft tissue metastasis (PNPCa) androgen-dependent PCa patient-derived xenograft tumor (PDX) model.
